Short-term results of endoscopic adjustable intra-gastric balloon for Japanese patients

【Background】Intragastric balloon is a well-established device for temporary treatment in obese patients. The Spatz3 adjustable intragastric balloon (AIGB) extends implantation to 1 year, decreases balloon volume for intolerance, and increases volume for diminishing effect.
【Aims】The aim of this study is to report our initial experience of the Spatz3 AIGB.
【Methods】One hundred and five patients were implanted by November 2020. First consecutive 63 patients (femal 37/male 26) who were followed up at least 1 year were retrospectively reviewed. Mean age was 47.0 years, body weight 85.4 kg and BMI 31.2 kg/m2.
【Results】At 1 year after implantation (at extraction), mean weight loss was 9.3 kg, BMI loss 3.4 kg/m2 and %excess weight loss (%EWL) 60.3%. >50% EWL was achieved in 45.2% and >25% EWL was achieved in 77.4% of the patients. Glucose intolerance and non-alcoholic fatty liver disease (NAFLD) improved significantly. Two patients required early removal due to intolerance. There were 3 severe adverse events (acute pancreatitis in 1, esophageal bleeding in 1 and gastric perforation in 1) occurred.
【Conclusion】AIGB seems to be viable as a treatment option for obesity, however, the possibility of severe complication specific to the prosthesis should be kept in mind.